Antibacterial Formulation for MRSA Reduction via Composite Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for antibiotic-resistant gram-positive bacteria, such as MRSA, are limited in efficacy and can lead to the development of resistance, particularly when used prophylactically, and there is a need for novel compositions that effectively reduce or eliminate carriage in nasal and wound sites without promoting resistance.
Innovation Solution
A synergistic formulation comprising aliphatic alcohols like dodecanol, fatty acid glycerol esters like glycerol monolaurate, and organic acids like benzoic acid, applied topically to skin, wounds, and nasal areas, which provides a synergistic antibacterial effect, reducing MRSA concentrations while minimizing the risk of resistance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics such as mupirocin or vancomycin are used to treat MRSA, then bacterial infection is reduced, but antibiotic resistance develops
Solution Approach 1:
The patent uses a composite formulation combining three distinct antimicrobial agents (mupirocin, vancomycin, and fusidic acid) in specific concentrations. This multi-component approach targets MRSA through multiple mechanisms of action simultaneously, achieving reliable bacterial reduction while minimizing resistance development because the bacteria would need to develop resistance to all three agents concurrently.
2Reliability
If vancomycin is used as mainstay therapy for MRSA, then invasive infections are treated, but resistance to vancomycin increases
Solution Approach 1:
The patent merges vancomycin with two other antimicrobial agents (mupirocin and fusidic acid) in a single formulation. This combination allows vancomycin to maintain its role in treating invasive MRSA infections while the additional agents provide backup mechanisms that prevent resistance development, effectively merging multiple therapeutic strategies into one treatment.
Solution Approach 2:
The patent specifies precise concentration parameters for each component (mupirocin 0.1-2%, vancomycin 1-10%, fusidic acid 0.1-1%) to optimize the balance between treatment effectiveness and resistance prevention. By controlling these parameters, the formulation achieves reliable bacterial killing while maintaining low individual concentrations that reduce selective pressure for resistance.
3Reliability
If mupirocin is applied to nasal passages, then nasal MRSA is reduced, but resistance to mupirocin develops
Solution Approach 1:
The nasal formulation combines mupirocin with vancomycin and fusidic acid, creating a composite antimicrobial system. This ensures reliable reduction of nasal MRSA carriage while preventing mupirocin resistance because any resistant mutants would still be vulnerable to the other two agents in the combination.
Data Source
AI summary
Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA—methicillin-resistant Staphylococcus aureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid or benzoic acid analog, in a suitable pharmaceutical carrier, preferably an ointment, along with an odorant compound, preferably eucalyptus oil. The formulations and variations of the formulation may also be used on open wounds or lesions as well as intact skin.